

Hydrix completes \$3.4m capital raise in support of near term growth initiatives

Hydrix Limited (ASX: **HYD**) (**Hydrix** or **Company**) is pleased to announce the successful completion of the retail component of its 1-for-2 pro-rata accelerated non-renounceable entitlement offer, as announced on Thursday, 15 September 2022 (**Entitlement Offer**).

Under the retail component of the Entitlement Offer (**Retail Entitlement Offer**), eligible shareholders were entitled to subscribe for 1 new fully paid ordinary Hydrix share (**Share**) for every 2 Shares held on the record date of 7.00pm (Melbourne time) on Monday 19 September 2022, at an issue price of 6 cents per Share. Eligible shareholders were also able to apply for any Shares offered under the Retail Entitlement Offer which were not validly applied for by shareholders under their respective entitlements (**Retail Shortfall Facility**).

Announcing the completion of the Retail Offer component, Executive Chairman, Gavin Coote commented:

"I am pleased our Board and existing shareholders along with new sophisticated and institutional investors, continue to endorse our medtech growth strategy for a new COVID-normal healthcare world.

"Funds raised will support the Services business +20% trend revenue growth for the year ahead which follows on from 40% revenue growth in FY22, the Medical segment's regulatory and market development activities to bring the world's only real-time heart attack alert device to market [The Guardian], and supporting our Venture investee companies as they approach major inflection points in the year ahead.

We remain resolute capitalising on the considerable opportunities we have created in the medtech space."

Results of Entitlement Offer

In addition to the \$2.07 million raised under institutional component of the Entitlement Offer (**Institutional Entitlement Offer**) (as announced on 19 September 2022), under the Retail Entitlement Offer, eligible shareholders subscribed for a total of 21.5 million Shares (to the value of \$1.29 million), bringing the aggregate amount raised under the Entitlement Offer to **\$3.36 million**.

The final application numbers under the institutional and retail components of the Entitlement Offer were as follows:

	No. of Shares	Subscription funds
Applications under Retail Entitlement Offer	17,421,877	\$1,045,313
Applications under Retail Shortfall Facility	4,125,153	\$247,509
Applications under Institutional Entitlement Offer	34,559,787 ¹	\$2,073,587
Total Applications	56,106,817	\$3,366,409

¹ All new Shares subscribed for under the Institutional Entitlement Offer, with the exception of 1,708,334 Shares subscribed for by entities related to Director Paul Lewis under the institutional shortfall bookbuild, were allotted on Friday 23 September 2022 and commenced trading on a normal settlement basis on the ASX on the same day. Hydrix intends to seek shareholder approval for the issue of the 1,708,334 New Shares to Director Paul Lewis' related entities at its upcoming annual general meeting.

The new Shares issued under the Retail Entitlement Offer will rank equally with existing Hydrix shares on issue. All new Shares subscribed for under the Retail Entitlement Offer will be allotted today, and will commence trading on a normal settlement basis on the ASX on Friday, 21 October 2022.

Shortfall Placement

The Directors, as permitted under ASX Listing Rule 7.2 Exception 3, reserve the right at their discretion to place any shortfall remaining (**Remaining Shortfall Shares**) after the satisfaction of applications for new Shares under the Retail Entitlement Offer (including applications under the Retail Shortfall Facility) (**Shortfall Placement**).

The Shortfall Placement is a separate offer, on the same terms and conditions as the Retail Entitlement Offer, and will remain open for up to 3 months after the Retail Closing Date. The Shortfall Placement may be offered to any investor who is not an eligible shareholder under the Retail Entitlement Offer, and who the Company invites to participate in the Shortfall Placement.

The allocation policy for the Shortfall Placement is outlined in the Company's Retail Offer Booklet, a copy of which was lodged with ASX on 21 September 2022.

Loyalty Options Offer and Annual General Meeting

Following the closure of the Entitlement Offer, and on the basis of the Company's post-Entitlement Offer capital structure, the Company will now finalise documents in relation to the Loyalty Options Offer, as announced to ASX on 8 August 2022.

The Company intends to lodge a prospectus in relation to the Loyalty Options Offer on or around Friday 28 October 2022, and dispatch its notice of meeting for Company's 2022 Annual General Meeting on the same day.

The Company confirms the new details for its 2022 Annual General Meeting as follows:

Date: 30 November 2022

Time: 10.00am (Melbourne time)

Location: Holding Redlich, Level 8, 555 Bourke Street, Melbourne VIC 3000

Further details of the Annual General Meeting will be set out in the notice of meeting.

-ENDS-

Authorisation: This announcement is authorised for release by the Board of Directors of Hydrix Limited.

Contact Details: For more information, please contact:

Company Enquiries:

Gavin Coote
Executive Chairman
info@hydrix.com
+61 3 9550 8100

Media Enquires:

Rod North
Managing Director, Bourse Communications
rod@boursecommunications.com.au
+61 3 9510 8309



About Hydrix Limited

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix's purpose is to enhance the health, safety, and wellbeing of a billion lives. The company leverages its powerful product innovation capability across three complimentary commercial business segments. These segments are **Hydrix Services**: design and engineer products that transform markets; **Hydrix Ventures**: invest in high potential medtech clients; and **Hydrix Medical**: distribute disruptive cardiovascular products.